PROFESSOR | Cardiovascular Surgery
Hi, my name is Gilbert Tang and I am the Surgical Director of the Structural Heart Program at the Mount Sinai Health System and a Professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai. I have performed over 3000 cases of transcatheter aortic valve replacement (TAVR), transcatheter mitral valve repair (transcatheter edge-to-edge repair) (TEER with MitraClip), transcatheter tricuspid valve repair (TriClip), and transcatheter mitral and tricuspid valve replacement procedures with excellent outcomes, on par with some of the top programs in the country. With our Structural Heart Team and Dr. David Adams’ mitral team at our Reference Valve Center, I work with a multidisciplinary group of cardiac surgeons, interventional cardiologists, imaging specialists, vascular surgeons and interprofessional staff to offer comprehensive, holistic care in patients with complex valve disease. Whether it is surgical reconstruction, transcatheter intervention or a hybrid approach, our team has the expertise and experience to deliver top-notched care to you and your family. Our TAVR program has recently earned the top 3-star rating in outcomes in the US ACC/STS TVT Registry, one of the few in the Tri-State area and in the country. During my career, I have achieved many “first” successes in the region and United States, including transcatheter mitral and tricuspid valve replacement and tricuspid valve repair with MitraClip, all performed via the groin without open surgery. Prior to Mount Sinai, I was the Director of the Valve Disease Center at Westchester Medical Center, playing a pivotal role in the launch of its Transcatheter Heart Program. My 24/7 “concierge” model of care has been well received and recognized in the New York area. As a regularly invited faculty and guest lecturer at national and international conferences, I am leading a number of innovative research projects in TAVR and transcatheter mitral and tricuspid valve therapies. I pioneered a technique to help better orient a transcatheter heart valve during TAVR to make it easier to reaccess the coronary arteries, and am leading several international registries in structural heart disease (EXPLANT-TAVR, CUTTING-EDGE, EXPLANTORREDO TAVR). Our collaborative research efforts and clinical results have been published in many top peer-reviewed medical journals and presented at many international conferences. I also had the fortune of training many physicians and heart teams to perform transcatheter valve procedures around the world. Currently, I am involved in several multicenter studies with leading institutions in the US and globally, and in a number of innovative clinical trials in aortic, mitral and tricuspid valve disease. In terms of my educational background, I received my bachelor's degree at Harvard University and MD at the University of Toronto, where I completed my residency in cardiac surgery as the Chief Resident at the Toronto General Hospital. I also completed a Master of Science in tissue engineering at the University of Toronto and an MBA at the Harvard Business School. Subsequently, I pursued specialized training at Mount Sinai Medical Center in New York focusing on complex mitral valve repair and TAVR, while also underwent advanced training in TAVR at the Leipzig Heart Center in Germany and the University of Pennsylvania. I am a Diplomat and Fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC), Fellow of the American College of Cardiology (FACC), and one of the very few surgeons to be a Fellow of the Society for Cardiovascular Angiography and Interventions (FSCAI). I look forward to the privilege of caring for you, your family and your loved ones. Thank you very much for the honor and the opportunity. Recent News: TCTMD: https://www.tctmd.com/news/non-coapt-patients-fare-well-mitraclip-expand-suggests Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests 6/9/22 By Michael O'Riordan "It was a sustained reduction in the COAPT-like patients, which is encouraging because these patients are supposed to be similar to the COAPT trial patients, as well as in the other [non-COAPT-like] patients." Cardiovascular News: https://cardiovascularnews.com/expand-registry-mitraclip-tvt-2022/ TVT 2022: EXPAND registry shows benefit of MitraClip in patients outside of COAPT trial criteria 6/9/22 "The real-world findings from this study show that excellent MR reduction and one-year outcomes were achieved by MitraClip not only in COAPT-like patients but also in a wider group of patients outside the COAPT criteria, meaning physicians may be able to help even more people with secondary MR." TCTMD: https://www.tctmd.com/news/tavi-turns-20-how-has-heart-team-evolved As TAVI Turns 20, How Has the Heart Team Evolved? 5/04/22 By Yael L. Maxwell "[Dr.] Tang urged more focus on patients’ individual circumstances in deciding what’s the best option for care. Family support and socioeconomics need to be considered, he said, when the Heart Team makes their recommendations." TCTMD: https://www.tctmd.com/news/surgery-ie-after-tavi-no-better-antibiotics-high-risk-patients Surgery for IE After TAVI No Better Than Antibiotics in High-Risk Patients 2/25/22 By Michael O’Riordan “Gilbert Tang, MD (Mount Sinai Medical Center, New York, NY), who wasn’t involved in the study, said the take-home message is that you shouldn’t take such sick patients to surgery, because it’s not going to help. He noted that heartfailure and stroke were common complications in this cohort of IE patients, affecting 42% and 10%, respectively. Also, more than a quarter of patients developed septic shock.” TCTMD: https://www.tctmd.com/news/some-adjustments-commissural-alignment-possible-tavi With Some Adjustments, Commissural Alignment Possible With TAVI 9/16/21 By Michael O'Riordan Gilbert Tang, MD, MBA (Mount Sinai Health System, New York, NY), who has investigated how to optimally align THVs with native aortic valve commissures, praised the investigators for their “provocative” study, saying it suggests it is possible to modify existing implantation techniques to optimize valve alignment. “It’s very elegant and nicely illustrated,” said Tang, “but it’s a small, proof-of-concept study that will require a larger number of patients to see if it can be broadly adaptable.” MedTech Outlook: http://cardiovascular.medicaltechoutlook.com/cxoinsight/perspectives-on-the-current-landscape-of-transcatheter-therapies-for-aortic-and-mitral-valve-disease-nwid-1595.html Perspectives on the Current Landscape of Transcatheter Therapies for Aortic and Mitral Valve Disease 2021 By Gilbert H. L. Tang As our understanding of valvular heart disease continues to evolve, newer transcatheter technologies will undoubtedly emerge, including updated designs from currently-approved systems. With a plethora of percutaneous therapies available on the market, interventional surgeons have to be well-versed with the various patient-, anatomy-, and device-specific factors that ultimatley lead to device selection. TCTMD: http://www.tctmd.com/news/timing-mitral-surgery-after-failed-teer-influences-outcomes Timing of Mitral Surgery After Failed TEER Influences Outcomes 7/21/21 By Todd Neale “Even though the TEER profile is safe based on the data out there, it’s important to avoid procedural complications and doing procedures on patients with right-sided heart failure and tricuspid regurgitation, because if it fails that leads to a higher mortality,” Tang told TCTMD. Mount Sinai Newsroom: http://www.mountsinai.org/about/newsroom/2021/mount-sinai-cardiovascular-doctors-to-receive-honors-during-american-college-of-cardiology-70th-annual-scientific-session Mount Sinai Cardiovascular Doctors to Receive Honors During American College of Cardiology 70th Annual Scientific Session 5/15/21 William Whang, MD, Associate Professor of Medicine (Cardiology), and Gilbert Tang, MD, MSc, MBA, Associate Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, are receiving the 2021 Simon Dack Awards for their exceptional contributions to the Journalof the American College of Cardiology (JACC) for their peer reviews. This journal ranks among the top cardiovascular journals in the world for its scientific impact.